Based on the development of ethics of laboratory animal in our and foreign countries and the related problems in our country, the necessity and feasibility of construction of the ethics censorship sys-tem about the laboratory animal were discussed and some adviees were raised to promote administration of la-boratory animal.

In this article, the authors expounded the necessary and problems of animal experiment post-ap-proval monitoring ( PAM) , which included who should do PAM, how to do PAM, and what the PAM can do. The authors also exposed the following suggestion: formulating the detailed rules, regulations and SOP, strengthening the training of PAM team member and animal experiment personnel, and monitoring the whole process of animal protocol review using the software.

OBJECTIVETo construct the P210(T315I-BCR/ABL) transgenic mice model.

METHODSThe transgenic vector in which the P210(T315I-BCR/ABL) gene and eGFP gene was derived by APN/CD13 promoter was constructed and microinjected into the single-cell fertilized eggs of C57 mice. Transgene integration was conformed by PCR genotyping and P210(T315I-BCR/ABL) expression levels was evaluated by RT-PCR. The CML phenotype was confirmed by blood routine examination, Wright's staining for peripheral blood and bone marrow smears, HE staining for organs of transgenic mice.

RESULTSThree transgenic mice lines with high expression of P210(T315I-BCR/ABL) gene and eGFP gene was selected. Compared with the wild type mice, the levels of WBC, platelet and neutrophil granulocyte of transgenic mice began to increase gradually at 2 months, and increase to 23.9×10⁹/L, 4 136×10⁹/L, and 74.6% respectively at 6 months. The remarkable hyperplasia of granulocytes was seen in the peripheral blood and bone marrow smears with splenomegaly infiltrated by leukemic cells.

CONCLUSIONThe P210(T315I-BCR/ABL) transgenic mice was constructed and provided a model to explore the mechanism of T315I CML and screen out the drug for T315 CML patient.

Animals ; Fusion Proteins, bcr-abl ; Genetic Vectors ; Genotype ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; Mice ; Mice, Transgenic ; Promoter Regions, Genetic